📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 13:52
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
12% Revenue Growth in Q1 FY27; <₹300 Cr Peptide Expansion Planned by 2028
Sai Life Sciences reported a 12% YoY revenue growth for Q1 FY27, led by a robust 26% growth in the CRO segment. The company is transitioning from a small molecule specialist to a multi-modality CRDMO, with a new peptide manufacturing facility planned for 2028 involving an investment of less than ₹300 crore (approx. 12% of current Net Worth). Management expects a stronger H2 FY27 as new capacity expansions go live. The company maintains deep relationships, currently serving 19 of the top 25 global pharmaceutical firms.
Confidence: HIGH
What changedThe company has detailed its strategic shift toward multi-modality services, including Peptides, ADCs, and Formulations, while confirming a ₹300 crore capex plan for commercial peptide manufacturing.
Why it mattersMoving into high-value modalities like peptides and ADCs (Antibody-Drug Conjugates) allows the company to capture a larger share of the global pharma R&D spend and improves long-term margin potential.
Q1 Revenue Growth: 12% YoYCRO Segment Growth: 26% YoYPeptide Capex: <₹300 CrPeptide Capex vs Net Worth: ~12%Top Pharma Clients: 19 of 25FY25 Capacity Utilization: 67%
📅 Short termThe outlook for the next few months is positive based on management's guidance for a stronger H2 FY27 and the upcoming launch of the formulation business.
📈 Long termThe structural shift toward becoming a multi-modality CRDMO by 2028 could significantly re-rate the business if execution on the peptide and ADC facilities remains on track.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the 2028 greenfield facility
- Volatility in global biotech funding impacting CRO demand
- Potential margin pressure during the initial ramp-up of new capacities
Key Highlights
Q1 FY27 revenue grew 12% YoY, with the CRO segment outperforming at 26% YoY growth.
Planned investment of less than ₹300 crore for a greenfield peptide manufacturing facility near Hyderabad, expected to be operational in 2028.
Currently serves 19 out of the top 25 largest global pharmaceutical companies, providing high revenue visibility.
Capacity utilization for FY25 stood at 67%, with new capacity for early-to-mid stage deliveries expected in H2 FY27.
Formulation business segment is projected to be operationally ready in approximately 6 months.
👀 What to Watch
Monitor the execution timeline of the new peptide facility and the operational launch of the formulation segment within the next two quarters. Watch for margin stability as the company ramps up new capacities in H2 FY27.
Q1 FY27 PAT up 22% to ₹73 Cr; Revenue grows 12% to ₹554 Cr with strong CRO momentum
Sai Life Sciences reported a steady Q1 FY27 with revenue growing 12% YoY to ₹554 Cr, led by a robust 24% growth in the CRO (Discovery) segment. Profitability improved significantly as PAT rose 22% YoY to ₹73 Cr, and EBITDA margins expanded to 27% from 25% in the previous year. The company continues its heavy investment phase, incurring ₹263 Cr in capex during the quarter (approx. 12% of TTM revenue). Management maintained its long-term revenue growth guidance of 15-20% and EBITDA margin targets of 28-30%.
Confidence: HIGH
What changedThe company has transitioned into FY27 with improved margins and strong growth in its Discovery (CRO) business, despite a slight sequential dip in revenue from Q4 FY26.
Why it mattersThe margin expansion to 27% and the 24% growth in CRO indicate high-value service delivery and strong relationships with 19 of the top 25 global pharma firms, supporting the company's premium valuation.
Q1 Revenue: ₹554 CrQ1 PAT: ₹73 CrYoY Revenue Growth: 12%Capex vs TTM Revenue: 12.05%EBITDA Margin: 27%Active Commercial Molecules: 33
📅 Short termThe stock may react positively to the 22% PAT growth and margin expansion, confirming the company's ability to maintain its guidance.
📈 Long termThe structural shift toward integrated CRDMO services and a 26% 5-year revenue CAGR position the company well for long-term growth in the global pharma outsourcing market.
⚠ Risk flags
- Volatility in global biotech funding impacting CRO segment visibility
- High capex intensity requiring sustained execution to maintain ROCE
- Forex fluctuations (₹1 Cr loss in Q1 vs ₹4 Cr gain YoY)
Key Highlights
Revenue increased 12% YoY to ₹554 Cr, with the CRO segment growing 24% YoY.
PAT grew 22% YoY to ₹73 Cr, while EBITDA margins improved by 200 bps to 27%.
CMC pipeline remains strong with 33 active commercial molecules and 14 late-phase molecules.
Incurred ₹263 Cr in capex during Q1 FY27 to expand R&D and manufacturing capabilities.
Capacity utilization for the quarter stood at 65% compared to 67% in FY25.
👀 What to Watch
Watch for the execution of the new 100,000 sq. ft. R&D facility in Hyderabad and the conversion of 14 late-phase molecules into commercial revenue streams.
22% PAT Growth in Q1 FY27; Revenue up 12% to ₹554 Cr with New R&D Facility
Sai Life Sciences reported a strong start to FY27 with a 22% YoY increase in PAT to ₹73 Cr. Revenue grew 12% YoY to ₹554 Cr, supported by a robust 24% growth in the CRO segment. EBITDA margins expanded by 200 basis points to 27%, reflecting improved operational efficiency. The company also operationalized a significant 100,000 sq. ft. R&D facility in Hyderabad to support its integrated CRDMO model.
Confidence: HIGH
What changedThe company has operationalized a major new R&D facility and achieved a 200 bps margin expansion compared to the same quarter last year.
Why it mattersThe growth in the CRO segment and the strengthening pipeline of 14 late-phase molecules validate the company's integrated 'Discovery to Delivery' strategy, which is critical for maintaining its high-growth trajectory.
Q1 FY27 Revenue: ₹554 CrRevenue vs TTM Revenue: 25.4%PAT Growth (YoY): 22%EBITDA Margin: 27%Late-phase molecules: 14New R&D Capacity: 100,000 sq. ft.
📅 Short termThe stock may react positively to the margin expansion and the double-digit bottom-line growth, especially given the operationalization of new capacity.
📈 Long termThe company's focus on integrated strategic engagements with top global pharma firms and its expanding late-stage pipeline suggest sustainable long-term growth potential.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High valuation with a P/E of 85.3
- Potential volatility in global biotech funding impacting CRO segment visibility
Key Highlights
Net Profit (PAT) increased 22% YoY to ₹73 Cr for the quarter ended June 30, 2026
Revenue from operations rose 12% YoY to ₹554 Cr, representing ~25% of TTM revenue
EBITDA margins improved to 27% from 25% in Q1 FY26
CRO business segment maintained strong momentum with 24% YoY growth
Operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad
👀 What to Watch
Investors should monitor the utilization rate of the new 100,000 sq. ft. R&D facility and the progression of the 14 late-phase molecules toward commercialization, which are key revenue drivers.
Rs 546.7 Cr Revenue in Q1; PAT Grows 22% YoY but Dips 30% Sequentially
Sai Life Sciences reported a standalone revenue of Rs 546.73 Cr for Q1 FY27, marking a 13.2% growth compared to the same quarter last year. Net profit for the quarter stood at Rs 71.34 Cr, up 22.2% YoY, but significantly lower than the Rs 102.53 Cr recorded in the preceding March quarter. The company maintained its focus on the CRDMO segment, though other income saw a sharp decline to Rs 3.54 Cr from Rs 10.01 Cr YoY. Additionally, the company expanded its equity base by allotting 5.06 lakh shares through ESOP exercises.
Confidence: HIGH
What changedThe company has transitioned into the new financial year with moderate YoY growth but a sequential contraction in profitability and revenue compared to Q4 FY26.
Why it mattersFor a high-valuation company (P/E 85.3), consistent sequential growth is often expected; the current QoQ dip may lead to a period of consolidation despite the healthy YoY improvement.
Standalone Revenue (Q1 FY27): Rs 546.73 CrStandalone PAT (Q1 FY27): Rs 71.34 CrYoY Revenue Growth: 13.2%QoQ Revenue Growth: -8.0%ESOP Shares Allotted: 506,782 units
📅 Short termThe stock may face some pressure or trade sideways in the short term due to the sequential decline in profit and revenue.
📈 Long termThe long-term outlook remains tied to the scaling of late-stage programs and the integrated CRDMO model, which targets 15-20% growth.
⚠ Risk flags
- Sequential decline in earnings
- High P/E valuation relative to growth
- Volatility in biotech funding impacting CRO segment
Key Highlights
Standalone revenue from operations grew 13.2% YoY to Rs 546.73 Cr.
Net profit increased 22.2% YoY to Rs 71.34 Cr, though it declined 30.4% on a QoQ basis.
Other income fell by 64.6% YoY to Rs 3.54 Cr from Rs 10.01 Cr.
Total expenses rose 9.6% YoY to Rs 454.94 Cr, driven by higher material and employee costs.
Allotted 506,782 equity shares of Rs 1 each following ESOP exercises during the quarter.
👀 What to Watch
Monitor the company's ability to sustain its target EBITDA margins of 28-30% in upcoming quarters. Investors should track the progress of the three products recently moved to the late-stage pipeline, as these are critical for commercial-scale revenue growth.
Sai Life Sciences FY26 PAT Jumps 109% to ₹355 Cr; Plans Massive ₹1,100-1,300 Cr Capex for FY27
Sai Life Sciences delivered a stellar performance in FY26, with consolidated revenue growing 29% YoY to ₹2,192 crore. Profitability saw a significant surge as PAT doubled to ₹355 crore, while EBITDA margins expanded by 508 bps to reach 30.1% due to strong operating leverage. The company has announced an aggressive front-loaded Capex plan of ₹1,100-1,300 crore for FY27 to support long-term demand from global pharma clients. Management has guided for a 15-20% revenue CAGR over the next 3-5 years with sustained margins of 28-30%.
Key Highlights
Consolidated revenue grew 29% YoY to ₹2,192 Cr, with the CDMO segment contributing 65% of total sales.
EBITDA increased 56% YoY to ₹661 Cr, with margins improving from 25.1% to 30.1%.
PAT surged 109% YoY to ₹355 Cr, reflecting high operational efficiency and growth in high-margin discovery services.
Planned FY27 Capex of ₹1,100-1,300 Cr is nearly double the FY26 spend, with 70% allocated to capacity expansion.
Maintains a strong portfolio with 34 active NCE commercial molecules and relationships with 19 of the top 25 global pharma companies.
👀 What to Watch
Investors should focus on the company's aggressive capacity expansion and its ability to maintain 30% margins despite heavy investments. The stock remains a strong play in the Indian CRDMO space given its deep integration with global big pharma and robust 15-20% growth guidance.
Sai Life Sciences Reports Strong FY26 Growth with 29% Revenue Rise and 29.8% EBITDA Margin
Sai Life Sciences has disclosed its Key Performance Indicators (KPIs) for the period FY22 to FY26, showcasing a robust growth trajectory. Revenue from operations increased significantly to 21,924.92 million in FY26, representing a 29.38% YoY growth. Profitability has seen a massive surge, with PAT margins expanding from 5.65% in FY24 to 15.91% in FY26. Additionally, the company has effectively deleveraged its balance sheet, with the Net Debt/Equity ratio dropping to 0.01 in FY26 from 0.75 in FY24.
Key Highlights
Revenue from operations grew 29.38% YoY to 21,924.92 million in FY26.
EBITDA margin expanded significantly to 29.78% in FY26, up from 20.48% in FY24.
PAT surged to 3,489.10 million in FY26, marking a 105.08% YoY growth.
Net Debt/Equity ratio improved to 0.01 in FY26 from 0.75 in FY24, indicating strong deleveraging.
Operational efficiency improved with Net Working Capital days reducing to 86 days in FY26 from 122 days in FY24.
👀 What to Watch
The company demonstrates exceptional fundamental growth and margin expansion, making it a strong contender in the CDMO/Life Sciences space. Investors should closely watch for upcoming listing or IPO developments as the financial health has improved drastically over the last three years.
Sai Life Sciences FY26 Net Profit Doubles to ₹355 Cr; EBITDA Margins Expand to 30%
Sai Life Sciences reported a stellar performance for FY26, with annual revenue growing 29% to ₹2,192 crore. The company's profitability saw a significant boost, with EBITDA rising 56% and Net Profit doubling to ₹355 crore. EBITDA margins improved significantly from 25% in FY25 to 30% in FY26, driven by operational efficiencies and a shift towards integrated discovery services. Despite a modest 4% revenue growth in Q4, the full-year trajectory remains strong with a substantial ₹633 crore capital expenditure investment for future growth.
Key Highlights
Full-year FY26 Revenue grew 29% YoY to ₹2,192 Cr, while Q4 Revenue rose 4% to ₹602 Cr.
EBITDA for FY26 surged 56% to ₹661 Cr, with margins expanding by 500 bps to 30%.
Net Profit (PAT) for the full year more than doubled, reaching ₹355 Cr compared to ₹170 Cr in FY25.
The company incurred a significant Capex of ₹633 Cr to expand integrated CRDMO capabilities and next-gen technologies.
Growth was primarily driven by deepening engagement with large pharma and momentum in integrated discovery services.
👀 What to Watch
Investors should focus on the significant margin expansion and the doubling of net profit as indicators of strong operational leverage. The substantial Capex investment suggests a robust pipeline and management's confidence in long-term demand within the CRDMO sector.
Sai Life Sciences FY26 PAT Jumps 97% to ₹3,415 Mn; Annual Revenue Up 31%
Sai Life Sciences delivered a robust performance for the financial year ended March 31, 2026, with annual revenue from operations growing 31.1% YoY to ₹21,532.26 million. The company's net profit (PAT) nearly doubled during the year, reaching ₹3,414.81 million compared to ₹1,734.62 million in FY25. For the final quarter (Q4 FY26), revenue grew 4.8% YoY to ₹5,943.40 million, while PAT increased by 14% to ₹1,025.32 million. The company also showed strong operational efficiency with net cash from operating activities rising to ₹4,952.69 million.
Key Highlights
Full-year FY26 Revenue from operations increased by 31.1% YoY to ₹21,532.26 million.
Annual Net Profit (PAT) surged by 96.9% YoY to ₹3,414.81 million from ₹1,734.62 million.
Basic Earnings Per Share (EPS) for FY26 rose to ₹16.27 from ₹9.00 in FY25.
Net cash generated from operating activities improved significantly to ₹4,952.69 million.
Property, Plant and Equipment assets increased to ₹14,808.39 million, reflecting major capacity expansion.
👀 What to Watch
Investors should take note of the significant margin expansion and doubling of profits, which indicate strong operational leverage. The substantial increase in fixed assets and capital work-in-progress suggests the company is positioning itself for continued growth in the coming years.
Sai Life Sciences Achieves 100% Renewable Power at Bidar Campus; First Indian CRDMO to do so
Sai Life Sciences has successfully transitioned its Bidar campus, including its flagship API and animal health facilities, to 100% renewable electricity. This milestone makes it the first Indian CRDMO to achieve such a feat at a site level, with 97% of power sourced directly from solar and wind. On an organizational level, nearly 80% of total electricity consumption is now renewable, resulting in zero market-based Scope 2 emissions. This transition avoids approximately 35,110 metric tonnes of CO2 emissions annually, significantly enhancing the company's ESG profile for global innovator clients.
Key Highlights
Bidar campus (Units IV and VI) reached 100% renewable electricity usage in FY26
Renewable energy share increased from 21% in 2020 to 89% in FY24 and 100% in FY26
Company-wide renewable energy consumption has reached nearly 80%
Avoids an estimated 35,110 metric tonnes of CO2 emissions annually
Infrastructure includes a 2.7 MW wind project under a group captive model
👀 What to Watch
Investors should recognize this as a significant ESG milestone that strengthens the company's competitive position with global pharmaceutical innovators. While not a direct financial metric, such sustainability achievements are increasingly critical for long-term contract wins and operational resilience.
Sai Life Sciences Receives GST Demand Order of INR 32.86 Crore
Sai Life Sciences Limited has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi, regarding GST discrepancies for the financial year 2021-22. The total demand amounts to INR 32.86 crore, which includes IGST, interest, and penalties. The issue stems from alleged excess Input Tax Credit (ITC) claims in GSTR-3B compared to GSTR-2A. The company has stated it will file an appeal at the Tribunal level and does not expect a material financial impact.
Key Highlights
Total tax demand of INR 32.86 crore issued by Karnataka tax authorities
Demand includes IGST of INR 16.28 crore and interest of INR 13.32 crore
Penalty of INR 3.26 crore imposed for alleged excess ITC claims in FY 2021-22
Company intends to contest the order by filing an appeal with the Tribunal
👀 What to Watch
Investors should monitor the outcome of the upcoming appeal as the demand represents a significant one-time liability. While the company expects a favorable outcome, any adverse ruling at the Tribunal level could impact short-term cash flows.
Sai Life Sciences Appoints Dr. John Pavey as Head of Global PR&D Effective April 1, 2026
Sai Life Sciences has announced a planned leadership transition within its Senior Management Personnel. Dr. John Pavey will take over as Head of Global Process Research and Development (PR&D) effective April 1, 2026, succeeding Dr. Dean David Edney who retires on March 31, 2026. Dr. Pavey brings over 20 years of global experience from top-tier pharmaceutical companies including Johnson & Johnson and AstraZeneca. This move ensures continuity in the company's critical R&D functions with a highly experienced industry veteran.
Key Highlights
Dr. John Pavey appointed as Senior Management Personnel (SMP) effective April 1, 2026
Dr. Dean David Edney to retire from the Head of Global PR&D role on March 31, 2026
Incoming leader Dr. Pavey has over 20 years of experience in CMC and chemical development
Dr. Pavey's career includes senior roles at Johnson & Johnson, UCB, and AstraZeneca
Transition focuses on maintaining expertise in API development, regulatory approvals, and sustainable manufacturing
👀 What to Watch
This is a routine management succession and should be viewed as a neutral event. Investors should monitor if the new leadership brings any strategic shifts to the company's R&D service offerings.
ICRA Assigns [ICRA]AA (Stable) and [ICRA]A1+ Ratings to Sai Life Sciences' Rs 768.60 Cr Debt
ICRA Limited has assigned high-grade credit ratings to Sai Life Sciences Limited for its total debt facilities of Rs 768.60 crore. The long-term fund-based facilities of Rs 550 crore received an [ICRA]AA (Stable) rating, while short-term non-fund-based facilities of Rs 218.60 crore were assigned [ICRA]A1+. These ratings reflect a strong credit profile and a high degree of safety regarding the timely servicing of financial obligations. The facilities are spread across major lenders including State Bank of India, IndusInd Bank, and Bank of Baroda.
Key Highlights
Assigned [ICRA]AA (Stable) rating for Rs 550.00 crore long-term fund-based facilities
Assigned [ICRA]A1+ rating for Rs 218.60 crore short-term non-fund-based facilities
Total rated debt instruments amount to Rs 768.60 crore across multiple banking partners
State Bank of India holds the largest share of rated limits at Rs 230.60 crore
The 'Stable' outlook indicates ICRA's expectation of maintained credit quality in the medium term
👀 What to Watch
Investors should view these high investment-grade ratings as a sign of financial robustness and low credit risk. No immediate action is required, but the ratings support a positive long-term outlook for the company's capital structure.
Sai Life Sciences Q3 FY26 PAT Surges 86% to ₹100 Cr; EBITDA Margins Expand to 34.4%
Sai Life Sciences reported a strong performance for Q3 FY26, with consolidated revenue growing 27% YoY to ₹556 crore. The company's profitability saw a significant boost as EBITDA rose 54% to ₹191 crore, driven by a 605 bps margin expansion to 34.4%. For the nine-month period, PAT grew by a massive 199% to ₹245 crore, reflecting robust operational leverage and healthy demand in the CDMO segment. The company is aggressively investing in capacity, with ₹405 crore of the planned ₹700 crore FY26 capex already deployed.
Key Highlights
Q3 FY26 Revenue increased 27% YoY to ₹556 crore, with CDMO services contributing 65% of total revenue.
EBITDA margins expanded significantly by 605 bps to 34.4%, outperforming the company's long-term guidance of 28-30%.
Net Profit (PAT) for the quarter jumped 86% YoY to ₹100 crore, while 9M FY26 PAT grew 199% to ₹245 crore.
Added 7 molecules to the late-phase and commercial pipeline during the year, taking the total to 43 molecules.
Invested ₹405 crore in capital expenditure out of a ₹700 crore plan for FY26 to expand manufacturing capacity by ~450KL.
👀 What to Watch
Investors should monitor the company's execution of its ₹700 crore capex plan and its ability to maintain margins above 30% as new capacities come online. The strong pipeline growth in late-phase molecules provides good revenue visibility for the coming years.
Sai Life Sciences Q3 FY26 PAT Jumps 86% to ₹100 Cr; 9M PAT Surges 199%
Sai Life Sciences reported a robust Q3 FY26 with revenue growing 27% YoY to ₹556 crore and PAT increasing 86% to ₹100 crore. The nine-month performance was even stronger, with PAT surging 199% to ₹245 crore on the back of 43% revenue growth. EBITDA margins expanded significantly by 605 bps to 34% in Q3, driven by improved capacity utilization and operational efficiencies. The company is on track with its ₹700 crore FY26 capex plan, having already invested ₹405 crore to enhance its CRDMO capabilities.
Key Highlights
9M FY26 Net Profit (PAT) skyrocketed by 199% YoY to ₹245 Cr from ₹82 Cr in the previous year.
Q3 FY26 Revenue grew 27% YoY to ₹556 Cr, while EBITDA rose 54% to ₹191 Cr.
EBITDA margins expanded to 34% in Q3 FY26 compared to 28% in Q3 FY25.
Invested ₹405 Cr in capital expenditure as of date against a total FY26 plan of ₹700 Cr.
Successfully completed 8 customer audits during the quarter with zero critical observations.
👀 What to Watch
The company is demonstrating exceptional growth and margin expansion that outperforms broader industry trends. Investors should maintain a positive outlook while monitoring the execution of the remaining ₹300 Cr capex and the sustainability of the 30%+ EBITDA margins.
Sai Life Sciences Q3 FY26 PAT Jumps 91% YoY to ₹976.3 Million; Revenue Up 28%
Sai Life Sciences reported a robust performance for the quarter ended December 31, 2025, with revenue from operations growing 28.1% YoY to ₹5,491.79 million. Net profit surged by 91.2% YoY to ₹976.30 million, even after accounting for a one-time exceptional loss of ₹82.93 million due to new labor code liabilities. The company has successfully utilized its entire IPO proceeds of ₹9,098.84 million, primarily for debt repayment, which has significantly reduced finance costs from ₹216.59 million to ₹80.61 million YoY. Operational efficiency is reflected in the Profit Before Tax, which grew 92.1% YoY to ₹1,304.69 million.
Key Highlights
Revenue from operations increased 28.1% YoY to ₹5,491.79 million from ₹4,286.02 million.
Net Profit (PAT) grew 91.2% YoY to ₹976.30 million compared to ₹510.57 million in the previous year.
Finance costs significantly decreased to ₹80.61 million from ₹216.59 million YoY following debt repayment.
Exceptional loss of ₹82.93 million recorded due to increased gratuity and leave liabilities under new Labour Codes.
Fully utilized IPO proceeds of ₹9,098.84 million, with ₹7,200 million used for debt repayment.
👀 What to Watch
The strong top-line growth and significant reduction in interest costs post-IPO debt repayment make this a positive result. Investors should monitor if the company can maintain these improved margins as it scales operations.
Sai Life Sciences Partners with Mabtech to Launch Immunology Research Hub in Boston
Sai Life Sciences has announced a strategic collaboration with Swedish firm Mabtech to establish its Boston laboratory as a US execution and demonstration hub for the EYRA platform. This partnership enables Sai to offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, to global biopharma clients. The EYRA platform allows for the simultaneous detection of dozens of analytes in a single run, significantly enhancing Sai's discovery and translational research capabilities. This move strengthens the company's competitive position in high-growth sectors like immuno-oncology, vaccines, and cellular therapy.
Key Highlights
Sai’s Boston site becomes a co-marketed US execution hub for the Mabtech EYRA platform
Joint delivery of advanced immunology services targeting immuno-oncology and cellular therapy
EYRA platform enables simultaneous detection of dozens of analytes with minimal hands-on time
Strategic expansion of US discovery operations to accelerate biopharma development timelines
👀 What to Watch
Investors should monitor the impact of this high-tech service expansion on Sai's US revenue growth and client acquisition. This collaboration enhances the company's value proposition in the specialized CRDMO market.
Sai Life Sciences Receives GST Penalty Order of ₹4.93 Crore for FY 2018-22
Sai Life Sciences Limited has received a tax order from the Additional Commissioner, Ranga Reddy GST Commissionerate, imposing a penalty of ₹4.93 crore. The demand is based on alleged excess Input Tax Credit (ITC) availment and discrepancies between B2B supply records and government portal data for the period FY 2018-19 to FY 2021-22. The company has stated its intention to file an appeal against this order, expressing confidence in a favorable outcome. While the penalty is significant, the company does not currently expect a material financial impact on its operations.
Key Highlights
Penalty of INR 4,93,36,015 (₹4.93 crore) imposed under Section 74 of the CGST/TGST Act.
Order relates to alleged excess ITC availment and B2B supply record differences.
The investigation covers a four-year period from financial year 2018-19 to 2021-22.
Company plans to contest the order through the formal appellate process.
Management currently assesses no material financial impact pending the appeal outcome.
👀 What to Watch
Investors should monitor the progress of the appeal as the penalty amount is noteworthy, though not immediately detrimental to the company's liquidity. No immediate action is required unless the appellate authority upholds the demand.
SAILIFE: Order passed u/s 73(9) of GST Act, demand of ₹32.86 Cr
Sai Life Sciences received an order from the Deputy Commissioner of Commercial Taxes (Audit), Bidar, DGSTO Kalaburagi under Section 73(9) of the Integrated Goods and Services Tax Act, 2017. The order demands ₹16,28,46,397 towards IGST, ₹13,31,50,353 as interest, and ₹3,25,69,279 as penalty, totaling ₹32.86 Cr. The demand relates to alleged excess availment of Input Tax Credit in GSTR-3B compared to GSTR-2A for FY 2021-22. The company plans to file an appeal and anticipates a favorable outcome, expecting no material financial impact.
Key Highlights
IGST demand of ₹16,28,46,397
Interest demand of ₹13,31,50,353
Penalty of ₹3,25,69,279
Order passed under Section 73(9) of the GST Act
Demand related to FY 2021-22
👀 What to Watch
Investors should monitor the progress of the appeal filed by the company. While the company anticipates a favorable outcome, any adverse development could potentially impact its financials.
SAILIFE: Order passed under GST Act with demand of ₹8.8 Cr
Sai Life Sciences has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi under the Karnataka Goods and Services Tax Act, 2017. The order demands IGST of ₹4,62,36,986, Cess of ₹291,659, Interest of ₹3,20,77,995, and a Penalty of ₹92,76,563, totaling approximately ₹8.8 crores. The demand relates to alleged excess availment of ITC and discrepancies in B2B supply records for FY 2020-21. The company plans to appeal the order and anticipates a favorable outcome, expecting no material financial impact.
Key Highlights
IGST demand of ₹4,62,36,986
Cess demand of ₹291,659
Interest demand of ₹3,20,77,995
Penalty of ₹92,76,563 imposed
Order passed under Section 107 (11) of the GST Act, 2017
👀 What to Watch
Investors should monitor the progress of the appeal process. While the company expects a favorable outcome, any adverse ruling could potentially impact its financials.
